Researchers have developed ICRAFT, an interactive computational platform designed to identify gene targets that enhance cancer immunotherapy. Unlike previous tools that focus on a single cell type, this resource integrates CRISPR screens and transcriptomic data to discover pathways with dual action in both cancer and T cells. The platform identified TNFAIP3 as a primary target whose deletion significantly improves anti-tumor immunity. In cancer cells, removing this gene increases susceptibility to immune-mediated killing, while in T cells, it boosts cytotoxic activity. Ultimately, ICRAFT serves as a comprehensive resource for the scientific community to accelerate the development of more effective immuno-oncology treatments.

References:

• Luo C, Zhang R, Guo R, et al. Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells[J]. Immunity, 2025, 58(3): 745-765. e9.